Granahan Investment Management’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.82M | Sell |
24,165
-1,885
| -7% | -$373K | 0.23% | 105 |
|
|
2025
Q4 | $4.93M | Buy |
26,050
+1,088
| +4% | +$209K | 0.21% | 109 |
|
|
2025
Q3 | $4.42M | Buy |
+24,962
| New | +$3.71M | 0.18% | 105 |
|
|
2022
Q2 | – | Sell |
-14,528
| Closed | -$1.02M | – | 183 |
|
|
2022
Q1 | $1.02M | Sell |
14,528
-96,305
| -87% | -$6.99M | 0.03% | 173 |
|
|
2021
Q4 | $10.7M | Sell |
110,833
-76,771
| -41% | -$7.09M | 0.22% | 108 |
|
|
2021
Q3 | $16.3M | Sell |
187,604
-72,988
| -28% | -$5.65M | 0.31% | 80 |
|
|
2021
Q2 | $21.3M | Sell |
260,592
-140,857
| -35% | -$11.7M | 0.4% | 62 |
|
|
2021
Q1 | $38.2M | Buy |
401,449
+91,527
| +30% | +$8.65M | 0.81% | 36 |
|
|
2020
Q4 | $19.2M | Buy |
309,922
+169,142
| +120% | +$9.64M | 0.43% | 59 |
|
|
2020
Q3 | $8.37M | Buy |
140,780
+65,635
| +87% | +$4.48M | 0.28% | 84 |
|
|
2020
Q2 | $5.24M | Sell |
75,145
-5,829
| -7% | -$370K | 0.19% | 106 |
|
|
2020
Q1 | $3.67M | Buy |
80,974
+61,865
| +324% | +$3.51M | 0.2% | 99 |
|
|
2019
Q4 | $1.24M | Sell |
19,109
-13,842
| -42% | -$925K | 0.06% | 154 |
|
|
2019
Q3 | $2.05M | Buy |
32,951
+4,833
| +17% | +$303K | 0.11% | 139 |
|
|
2019
Q2 | $2M | Sell |
28,118
-26,503
| -49% | -$1.95M | 0.1% | 142 |
|
|
2019
Q1 | $4.28M | Sell |
54,621
-60,995
| -53% | -$4.62M | 0.23% | 106 |
|
|
2018
Q4 | $9.79M | Buy |
115,616
+74,116
| +179% | +$7.9M | 0.69% | 51 |
|
|
2018
Q3 | $7.11M | Buy |
41,500
+12,814
| +45% | +$1.93M | 0.39% | 81 |
|
|
2018
Q2 | $3.71M | Sell |
28,686
-25,067
| -47% | -$2.8M | 0.22% | 118 |
|
|
2018
Q1 | $5.54M | Sell |
53,753
-8,586
| -14% | -$849K | 0.4% | 85 |
|
|
2017
Q4 | $5.33M | Buy |
62,339
+5,798
| +10% | +$503K | 0.42% | 85 |
|
|
2017
Q3 | $4.8M | Buy |
56,541
+4,171
| +8% | +$330K | 0.4% | 90 |
|
|
2017
Q2 | $3.97M | Buy |
52,370
+4,359
| +9% | +$305K | 0.37% | 94 |
|
|
2017
Q1 | $3.17M | Sell |
48,011
-472,964
| -91% | -$31.1M | 0.32% | 101 |
|
|
2016
Q4 | $33M | Buy |
520,975
+31,380
| +6% | +$1.98M | 1.13% | 21 |
|
|
2016
Q3 | $31.2M | Sell |
489,595
-31,098
| -6% | -$2.28M | 1.02% | 20 |
|
|
2016
Q2 | $38.7M | Sell |
520,693
-92,653
| -15% | -$6.88M | 1.41% | 7 |
|
|
2016
Q1 | $41M | Buy |
613,346
+38,472
| +7% | +$2.34M | 1.49% | 7 |
|
|
2015
Q4 | $38.9M | Sell |
574,874
-51,899
| -8% | -$3.2M | 1.34% | 9 |
|
|
2015
Q3 | $33.5M | Buy |
626,773
+66,364
| +12% | +$4.03M | 1.04% | 19 |
|
|
2015
Q2 | $35.3M | Buy |
560,409
+340,317
| +155% | +$18.6M | 1% | 25 |
|
|
2015
Q1 | $10.6M | Buy |
+220,092
| New | +$8.43M | 0.3% | 124 |
|
Other funds holding LGND
VPM
VCM
NAMI
CC
Granahan Investment Management's LGND Position: Q1 2026 in Review
Granahan Investment Management reduced its Ligand Pharmaceuticals (LGND) stake by 7.2% in Q1 2026, selling an estimated $373K and leaving 24,165 shares worth $4.82M. The position accounts for 0.23% of the portfolio, ranked #105.
Granahan Investment Management first reported a position in LGND in Q1 2015 and has held it in 32 quarters since. The position peaked at $41M in Q1 2016. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.
- Granahan Investment Management held 24,165 shares of Ligand Pharmaceuticals worth $4.82M as of Q1 2026.
- Granahan Investment Management sold 1,885 Ligand Pharmaceuticals shares in Q1 2026, an estimated $373K.
- Ligand Pharmaceuticals made up 0.23% of Granahan Investment Management's portfolio in Q1 2026, its #105 holding.
- Granahan Investment Management first reported a position in Ligand Pharmaceuticals in Q1 2015 and has held it in 32 quarters since.
- Granahan Investment Management's Ligand Pharmaceuticals position peaked at $41M in Q1 2016.
- 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.
Based on Granahan Investment Management's 13F filing for Q1 2026, filed 15 May 2026.